The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Phase 3
Completed
- Conditions
- Gastric Cancer
- Interventions
- Registration Number
- NCT02395640
- Lead Sponsor
- Fudan University
- Brief Summary
This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.
- Detailed Description
This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 438
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description EOX Capecitabine Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14； XELOX Oxaliplatin oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14； EOX Epirubicin Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14； XELOX Capecitabine oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14； EOX Oxaliplatin Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
- Primary Outcome Measures
Name Time Method progression free survival 7 months
- Secondary Outcome Measures
Name Time Method overall survival 10 months quality of life questionnaire 2 months overall response rate 2 months Number of Participants with Adverse Events 2 months
Trial Locations
- Locations (1)
Fudan University Cancer Hospital
🇨🇳ShangHai, Shanghai, China